Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Early treatment with interferon beta-1a may delay MS onset
Washington, DC-Early treatment of patients at high risk for developing multiple sclerosis (MS), i.e., those with optic neuritis, may be beneficial. The use of interferon beta-1a in these patients at the first sign of optic neuritis or other neurologic symptoms with silent lesions on magnetic resonance imaging (MRI) may significantly delay the development of MS.
Related Videos
Related Content
